Early changes in bone marrow morphology induced by thalidomide in patients with refractory myeloma

Alessandro Corso, Angela Lorenzi, Patrizia Zappasodi, Rosangela Invernizzi, Laura Vanelli, Mario Lazzarino

Research output: Contribution to journalArticle


Bone marrow morphology and the number of CD34+ cells were evaluated in 17 patients with refractory multiple myeloma at the start of therapy with low-dose thalidomide and after 3 months. All responding patients showed an evident increase of cellularity, reappearance of erythroblasts and myeloid precursors in various phases of differentiation, and an increase of megakaryocytes. Nine of the ten responders also had increase of bone marrow CD34+ cells.

Original languageEnglish
Pages (from-to)958-960
Number of pages3
Issue number8
Publication statusPublished - Aug 1 2003



  • CD34 cells
  • Morphology
  • Multiple myeloma
  • Refractory disease
  • Thalidomide

ASJC Scopus subject areas

  • Hematology

Cite this